: There is no simple answer to this because, as far as we can see from enquiries made to us nowadays, polypharmacy, or polytherapy, is so common that we hardly ever see acute poisoning attributable to one agent. There may be one principal agent, but there are nearly always three, four or five that may be involved as well. Naturally the most spectacular of the interactions are those in people on monoamine oxidase inhibitors who are given something else and then something dramatic happens. But there are all sorts of interactions beyond that. The commonest cases of poisoning from drugs are undoubtedly attributable to those agents which are used for mental trouble or used in psychiatric practice. It is interesting that the plea has been made by a number of eminent psychiatrists that we should encourage them in the use of certain of these drugs because, by treating successfully patients with depression, they will save people from the grave by their own hand. In my opinion, and figures of suicide rate lately collected support this, they are merely putting drugs in the hands of people who want to kill themselves. Professor M D Milne: I entirely endorse Dr Goulding's views. I think the main trouble for the clinician is to discover what the poisoning agent is. One gets a bewildering amount of polypharmacy in would-be suicides and I think it prevents any scientific therapy other than symptomatic treatment in many cases. Only if you really know the chief poison, suchas phenobarbitone, can you say 'we must hcmodialyse or give specific treatment'.
Lord Cohen: On the regretful assumption that alcohol is a drug: In What Position on the Table  does Alcohol and Barbiturate Interaction come into this Acute Poisoning? Dr Goulding: I have always regarded this explanation as a kindness on the part of the pathologist giving evidence in the Coroner's court, because then the death becomes an accident and not a deliberate measure. I have no doubt that if a sufficient quantity of alcohol is taken with a sufficient quantity of barbiturate it would have an additive effect, but it is unjustifiable to assume that a person has died by accident just because he has had one or two glasses of sherry and then taken a few barbiturate tablets. I do not think that is the case.
Lord Cohen: The next question is: What Types of Drugs can Cause Bleeding in Patients Already on Anticoagulants and What is the Explanation? Dr J J Burns: Pharmacology textbooks point out the hazards of giving large doses of salicylates in conjunction with various coumarin anticoagulants. Salicylates have an effect on prothrombin synthesis and thus they can have an additive or perhaps synergistic effect to the action of dicoumarol and this drug combination may lead to bleeding. Recent reports indicate that phenylbutazone potentiates the action of warfarin, and this can lead to an exaggerated prothrombin response. This effect appears to result from an inhibition of phenylbutazone on warfarin metabolism. The third possibility is something I mentioned in my paper. If a patient is controlled on dicoumarol while receiving phenobarbitone, it is conceivable that when the phenobarbitone is removed the prothrombin time will be elevated. This results from the fact that the metabolism of dicoumarol which was stimulated by phenobarbitone will return to its normal rate and thus the drug will exert a greater anticoagulant action. Dr B B Brodie: In my paper I mentioned that coumarin anticoagulants are acidic and highly bound by plasma proteins; other drugs which are acidic may compete for the same binding site, thereby increasing the activity of the anticoagulant by displacing it. There have been a number of papers describing bleeding which can occur in this way.
Lord Cohen: Can Drlug Displacemsent from Storage
Sites be Reversed to Treat Poisoning? Dr Brodie: I do not know but I could guess. I have read a paper (G B Odell, 1959, J. Pediat. 55, 268) about newborn, especially premature, babies who do not have very much albumin. Any drug that competes with bilirubin for the same binding sites may displace it. The bilirubin can then go to the central nervous system and cause quite severe toxic effects. This is one of the reasons, of course, why it is unsafe to give these children salicylates or sulphonamides and a number of other acidic drugs which will compete with bilirubin for the binding site. I remember this paper suggesting that albumin should be given to these children, not to lower the bilirubin, but just to fasten it up until the danger is over. I do not know whether it has ever been done, or what the results were. Dr Goulding: Hitherto, as Professor Milne has said, the treatment of acute poisoning, or indeed chronic poisoning for that matter, is largely unscientific, and certainly unpharmacological or apharmacological, and largely a matter of general medical management. Contrary to what editors of popular magazines seem to imply, there is really a great sparsity of specific antidotes. Nevertheless, there are a few and as far as removing toxic agents from the receptor sites is concerned (using the term generally, not as specifically defined in this meeting), we have got a few specific agents after all. One that we have been very interested in, though fortunately we have had very limited opportunities to study it in clinical practice, is the use of oximes in poisoning by organophosphorus compounds. When the organophosphorus compound gets linked to cholinesterase, it can be displaced by these oximes. The interesting thing is that the oximes must be given very early on in the incident. Recently we had a case where we could try the effect of these compounds some time after the organophosphorus compound was taken, and then we found it had no effect at all. I think we have got an increasing number of examples of specific agents in poisoning with chelators and, particularly, with desferrioxamine for iron. We are getting more of these, but the list is still very limited.
I was interested to hear what Dr Burns said about stimulating the liver microsomes, and I could not help thinking that, contrary to our line of reply to the first question, perhaps we should encourage chronic multiple drug-taking on a modest level to get the microsomes going more actively and then perhaps when anything new hit the body they would be able to deal with it more effectively, but perhaps this is too fanciful. On the other hand it is quite interesting to see the way in which certain drugs, as it were, stimulate their own metabolism and one cannot help feeling, looking to the future, that this principle might be developed, particularly for dealing with barbiturate intoxication which is such a common feature in this country at present. Professor Milne: It seems to me logical, in any patient with suspected hypo-albuminaemia and poisoning with an albumin-bound poison, that albumin infusions would be well worth trying as a first aid measure. It can be run in fairly rapidly. I was interested in the account by Dollery, Emslie-Smith & Muggleton (1961, Brit. J. Pharmacol. 17, 488) of the excess binding of pempidine in the chlorothiazide patient. So far as I know this is the one example which has ever been described in which one drug increases the binding of another, or am I mistaken in this? It seems to be a very unusual phenomenon that a drug such as chlorothiazide will increase the binding of another, whereas displacement is relatively well known. Dr C T Dollery: I do not know of another example. Chlorothiazide binds to protein in a ratio of 0 7 to 1 and it is interesting that the binding of pempidine to protein is in the same ratio. One explanation of this phenomenon would be that a weak combination occurs between chlorothiazide and pempidine. However, some of the observations could not be explained in this way.
I do not know of any well-documented instance where protein binding has proved a useful method of treating acute poisoning.
Lord Cohen: Many people seem to have been interested by Professor Milne's manipulation of urinary pH. Would you please explain, Professor Milne: How do you Manipulate Urinary pH? Professor Milne: Experimentally the safest and most innocuous ways of manipulating urinary pH are by giving oral sodium bicarbonate and oral ammonium chloride. These will produce the maximum range of pH without any demonstrable deleterious effect, and many times I have been the victim of this. But in the treatment of poisoning one wants a very rapid effect. It is no use manipulating the pH if it is going to take several hours, by which time the patient may be either dead or recovered.
Alkalinization is easy; intravenous sodium bicarbonate or sodium lactate is quite safe and will rapidly alkalinize the urine. This is one occasion where I would say the hated bladder catheter is absolutely essential. One must have an indwelling catheter in these patients and be modulating the urinary pH. A pH meter is absolutely essential; it is not enough to dip in litmus and say 'alkaline'. One must have a figure of urinary pH.
Acidification of the urine, which one might wish to use, say, in amphetamine poisoning, is rather more difficult. Oral ammonium chloride takes a fair time to act; intravenous ammonium chloride, depending on the speed at which it is given, can be extremely dangerous and may cause convulsions. The only safe agent to use intravenously is arginine hydrochloride which is rapidly acidifying; 10 or 20 g of arginine hydrochloride is well tolerated by rapid intravenous drip within, say, half an hour. The only snag is that one would not usually have this preparation available sterile in the dispensary. It may horrify the bacteriologists, but if I thought this was lifesaving, I would be prepared to tip in 10 or 20 g of arginine hydrochloride from a clean bottle into sterile 5 % glucose and administer it intravenously. This sort of mancuvre has often saved lives in cholera when the preparation of sterile solutions is impossible, and I think that if a procedure could be life-saving, and time is extremely important, sterility can occasionally be risked. I may be heretical in saying this; all I know is it has saved lives in cholera.
Lord Cohen: In What Circumstances Should Toxicity Resulting from Enzyme Induction be Looked for? And, as an addendum: Are there Species Differences? Dr Burns: In most cases drugs stimulate the inactivation of drugs, so toxicity would not necessarily result from enzyme induction. However, animal studies have shown that phenobarbitone and other drugs markedly potentiate the toxicity of certain organophosphate insecticides by stimulating their conversion to toxic metabolites. There may be instances in human therapy where a metabolite that is formed from a drug is also toxic so that enzyme induction may result in toxicity.
To answer the second part of the question, there appears to be species differences in enzyme induction. For instance, the chronic administration of phenylbutazone to dogs results in a marked increase in the drug's metabolism. However, this does not occur in human subjects receiving phenylbutazone since there is no decline in plasma levels of the drug on prolonged administration of the drug. In addition, Professor Remmer (1965, Ann. N. Y. Acad. Sci., 123, 79) has shown that enhanced metabolism of tolbutamide can explain tolerance to the drug's hypoglycaemic action in dogs. However, this effect seems not to occur in man. Dr Brodie: There is not much I can add, except that one gets a little concerned about the effects of drugs in general on the toxic effects of environmental chemicals. Many people take drugs every day of their lives and, at the same time, are taking in chemicals from tobacco-smoking, smog and so forth. A number of instances are known of a carcinogen being formed as a metabolite of a compound that is not itself a carcinogen. It is possible that substances in smog or tobacco are converted to carcinogens in the body. The induction of drug-metabolizing enzymes might facilitate the formation of harmful substances from inherently harmless precursors. This merely stresses the importance of learning the nature of the harmful substances in tobacco and smog so that the problem can be approached intelligently.
About the question of whether there are differences in enzyme inductiona dramatic example is latent porphyria. A number of drugs induce the formation of delta-aminolhvulinic acid synthetase, an enzyme responsible for the formation of delta-aminolkvulinic acid, the precursor of the porphyrins. An occasional person has something wrong with the gene which controls this induction. When he takes a certain drug, usually with an allyl side-chain, the induction goes wild. Huge amounts of the enzyme catalyse the formation of huge amounts of the precursor. The steps leading to porphyrins are overwhelmed by the excess of substrates and, for some reason not understood, the wrong type of porphyrins are formed. These have very bad effects and the patients often die. Dr Goulding: I have only been interested in a very speculative way in this enzyme induction. That is in dealing with these new pesticides, a number of which are ingested by us as residues in the food. Most of them, if not all, have been studied metabolically before they are put on the market, and what always amazes me is the finding that nearly every one (there are a few exceptions) is metabolized by the body. These are very often entirely new chemicals, quite diverse from anything found hitherto in nature, or likely to be encountered previously by the body. I am always slightly puzzled that the body can adapt its enzyme system, or bring its enzyme system to bear to deal with these things, which are so very foreign and novel. Dr Brodie: It looks as though the enzymes that metabolize most drugs are already in the body. They are extraordinarily nonspecific in order to handle, not so much drugs, but any lipid-soluble foreign compounds which have been present in the food of land-living animals ever since they crept out of the sea. Without such enzymes all the alkaloids and terpenes in food would accumulate to toxic levels since the kidney could not excrete them. I suspect that the tremendous species differences in the metabolism of these substances may reflect differences in food habits of these animals many millions of years ago. There are far greater differences in enzymes for foreign compounds than in enzymes of intermediary metabolism.
Lord Cohen: Is There any Specific Antagonist in Overdosage of Cardiac Glycosides? Dr Goulding: No, there certainly is not, so far as I am aware. This is one of the nightmare questions we get, and I hope someone will come up and answer it for me. We just do not know what to do in these cases and all sorts of advice has been given by all sorts of people, chiefly centred around administering potassium. I wondered whether, if we controlled the myocardial hyperexcitability by administering quinidine or procainamide and then tided the patient over the period until they could excrete these drugs by using an artificial pacemaker, this would be a way out of these fortunately rare crises. They are a great worry to us. Lord Cohen: Is there any member of the panel with any suggestions about antagonizing cardiac glycosides ? Professor Milne: Is pronethalol any use here? I always thought that this was a very useful agent in this respect, but I may be wrong. Dr Brodie: What does potassium do? Does it help at all? Dr Goulding: Doubtfully, I would think. Dr Doliery: I can confirm what Professor Milne said about pronethalol. It is now more usual to employ propanolol because pronethalol produces tumours in mice. If these drugs are not available and there is extreme urgency, a digitalis arrhythmia can be reversed by the use of EDTA to lower serum calcium. Treatment with oral potassium is very useful in less serious situations, but intravenous potassium is potentially very dangerous unless given in dilute solution. Professor D R Laurence (University College Hospital, London): Pronethalol and propanolol both have quinidine-like actions in addition to their 3-adrenergic blocking effect. It is still uncertain what part is played by each of these actions in controlling arrhythmias. We have knowledge of a 3-adrenergic blocking drug without quinidinelike action. It does not oppose digitalis-induced arrhythmias in animals.
Lord Cohen: One of our friends from Holland has asked this question. A patient treated with phenobarbitone took a large overdoseit was a suicidal attemptof dicoumarol. The patient was given vitamin K andphenobarbitone and recovered.
(1) Would this Overdose be Metabolized much Faster than would be Expected? (2) Would Phenobarbitone Interact with Vitamin K? Dr Bums: In answer to the first part of the question, it would appear from our data that an overdose of dicoumarol would be metabolized more rapidly in the patient treated with phenobarbitone.
With regard to the second question, I do not know what effect barbiturates have on vitamin K metabolism. However, I might point out something I did not discuss in my paper. The first paper which described an effect of barbiturates on coumarin anticoagulants was published in South America and suggested that barbiturates had vitamin-K-like activity (Avellaneda, 1955, Medicina, B. Aires 15, 109) . These investigators noted that barbiturates antagonize the effect of certain coumarin anticoagulants. This was a purely clinical observation but it took at least six years to explain it on a metabolic level. Lord Cohen: Still, this would not be the first time that an accurate observation had to wait for its correct explanation.
Lord Cohen: The next question: Is it Essential for Liver Microsome Enzymic Inactivation that a Drug be Unbound? Is it True t1at only the Unbound Fraction is Metabolized? Dr Brodie: There is a mix-up in terms here. The rate of metabolism is proportional to the concentration of unbound drug. The unbound drug is in equilibrium with bound drug. Hence, as the unbound drug is metabolized, more of the bound drug breaks down to the unbound drug, and so on until it is all metabolized. Lord Cohen: Ultimately, enzymic inactivation is complete, of course, whether it is bound or unbound.
Lord Cohen: Does any Member of the Panel have any Clinical Experience of the Antagonism of Guanethidine by Ephedrine ? Dr Brodie: If ephedrine acts like amphetamine, it will antagonize guanethidine by displacing it from the catecholamine storage sites where guanethidine is taken up.
